Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
L-756423 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| L-756423 | DRUG | - |
| Indinavir sulfate | DRUG | - |
Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 18 years old. * Have a viral load of at least 1,000 copies/ml. * Have a CD4 cell count of at least 100 cells/mm3. * Have experienced treatment failure (your viral load increased significantly) within 2...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
L-756423 is an investigational small molecule being studied for the treatment of HIV infections. It was evaluated in a Phase 2 clinical trial in combination with indinavir in HIV-positive patients who had previously taken indinavir. The drug is not approved and remains in clinical development.
L-756423 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company conducted a Phase 2 clinical trial of the drug for HIV infections.
L-756423 is in Phase 2 clinical development. It has completed one Phase 2 trial, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
L-756423 has been studied in one completed Phase 2 trial, NCT00002452, titled "A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir." The trial enrolled 30 participants in the United States.
No, L-756423 is not the same as indinavir. In the clinical trial NCT00002452, L-756423 was studied in combination with indinavir, meaning they are separate drugs. The trial evaluated the safety and effectiveness of adding L-756423 to indinavir in HIV-positive patients.